^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD30-targeted antibody-drug conjugate

    Related drugs:
    2d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=58, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns
    Trial termination
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    10d
    Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027
    Trial completion date
    |
    clonoSEQ
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin)
    11d
    BRESELIBET: BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (clinicaltrials.gov)
    P2, N=150, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Active, not recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cytarabine • Adcetris (brentuximab vedotin) • methylprednisolone sodium succinate
    11d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Completed --> Active, not recruiting
    Enrollment closed
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    14d
    Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy. (PubMed, Cell Mol Immunol)
    Furthermore, the addition of eliglustat also enhanced the tumor-killing activity of brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, both in vitro and in vivo. This glycoimmunotherapy paradigm represents a clinically actionable approach to overcome glycan-mediated immune evasion and enhance therapeutic efficacy in CD30-positive lymphomas.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    15d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Completed, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Completed
    Trial completion
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    18d
    SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions. (PubMed, Clin Lymphoma Myeloma Leuk)
    Brentuximab vedotin-based regimens have reshaped frontline therapy for CD30-positive disease, while ongoing studies are exploring the role of novel therapies including epigenetic modulators, phosphatidylinositol 3-kinase (PI3K) and JAK inhibitors, and immune-based therapies across the PTCL spectrum. Future progress will depend on biomarker-driven clinical trials, refined patient selection, and the incorporation of genomic and immune signatures to personalize therapy.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin)
    18d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Apr 2029 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    18d
    A single-arm, open-label, multicenter exploratory clinical trial of brentuximab vedotin combined with chidamide for the treatment of CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL) patients (ChiCTR2600119766)
    P=N/A, N=33, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    21d
    ECHELON-3: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P3, N=239, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Adcetris (brentuximab vedotin)
    28d
    S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    1m
    BRESELIBET: BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    cytarabine • Adcetris (brentuximab vedotin) • methylprednisolone sodium succinate